Quick answers
- What is Amisulpride used for?
- The FDA-approved label (Barhemsys, Acacia Pharma Ltd, June 17, 2026) says: “BARHEMSYS ® is indicated in adults for: prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. BARHEMSYS is a dopamine-2 (D 2 ) antagonist indicated in adults for …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Amisulpride have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Amisulpride?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Amisulpride been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Amisulpride?
- 1 company lists prescription products of Amisulpride in the FDA NDC Directory, including Acacia Pharma, Ltd..
What Amisulpride is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
BARHEMSYS ® is indicated in adults for: prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. BARHEMSYS is a dopamine-2 (D 2 ) antagonist indicated in adults for …
— FDA label: Barhemsys, Acacia Pharma Ltd, effective June 17, 2026. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Forms and how it is given
| Dosage forms | Injection, solution |
|---|---|
| Route | Intravenous |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Barhemsys |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Acacia Pharma, Ltd.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA209510 BARHEMSYS | Lxo Ireland | February 26, 2020 | 4, latest September 14, 2022 2022: Labeling · 2022: Labeling · 2021: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2284232, 2284237, 2467148, 2467149 |
|---|---|
| SPL set ID of the quoted label | ab23bc6e-b6a8-165f-e053-2a95a90ab144 |
| FDA labels (SPL) | 1 |
| FDA applications | NDA209510 |
| Active ingredients (FDA) | AMISULPRIDE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Barhemsys, Acacia Pharma Ltd, effective June 17, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →